Tae Il Kim | Oncology | Research Excellence Award

Published on by NESIN Awards

Prof. Tae Il Kim | Oncology | Research Excellence Award

Professor | Yonsei University College of Medicine | South Korea

Dr. Tae Il Kim is a distinguished researcher at Yonsei University College of Medicine in Seoul, South Korea, specializing in gastroenterology, colorectal cancer, and precision oncology. He has authored 337 Documents, which have received 8,659 citations, and holds an h-index of 46, reflecting his substantial global impact in biomedical and clinical research. Dr. Kim’s work focuses on translational and clinical studies that advance the understanding, diagnosis, and treatment of colorectal cancer and related gastrointestinal disorders. His notable contributions include elucidation of the HER2-ELF3-KRAS signaling axis in KRASG13D colorectal cancer, development of a novel risk score for 30-day adverse events following colonoscopy in older adults, and identification of circulating RNA biomarkers associated with the adenoma–carcinoma sequence. He has also pioneered multi-omic and machine learning-based approaches for precision oncology, including the CAN-Scan platform and non-invasive screening tools for early detection, as well as genome-wide association studies on nonhereditary colorectal polyposis and its recurrence. Dr. Kim collaborates extensively with over 800 co-authors across diverse disciplines and institutions, demonstrating a commitment to interdisciplinary and international research networks. His work has significantly contributed to improved patient care, early diagnosis, personalized therapeutic strategies, and the translation of scientific discoveries into clinical practice. By integrating innovation, rigorous research, and collaboration, Dr. Kim continues to shape the future of gastroenterology and oncology, enhancing global knowledge, advancing precision medicine, and elevating the visibility of Korean medical research on the international stage, with a tangible societal impact through better patient outcomes and public health advancements.

Profiles: Scopus | ORCID

Featured Publications

Kim, T. I., et al. (2025). Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes: Cellular and Molecular Biology. British Journal of Cancer. (Citations: 3)

Kim, T. I., et al. (2025). Circulating RNA markers associated with adenoma–carcinoma sequence in colorectal cancer. International Journal of Molecular Sciences. (Citations: 3)

Kim, T. I., et al. (2025). CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Reports Medicine. (Citations: 2)

Kim, T. I., et al. (2025). Machine learning-enabled non-invasive screening of tumor-associated circulating transcripts for early detection of colorectal cancer. International Journal of Molecular Sciences. (Citations: 2)

Kim, T. I., et al. (2025). Identification of genetic factors related with nonhereditary colorectal polyposis and its recurrence through genome-wide association study. Journal of Gastroenterology and Hepatology Australia.(Citations: 1)

Sara Mogedano Cruz | Oncology | Young Scientist Award

Published on by NESIN Awards

Mrs. Sara Mogedano Cruz | Oncology | Young Scientist Award

Universidad Europea de Madrid | Spain

Sara Mogedano-Cruz is a developing scholar in the field of biomedical and clinical sciences, affiliated with the Universidad Europea de Madrid in Villaviciosa de Odón, Spain, where she focuses on anatomical variability, anthropometric modeling, and evidence-based approaches to improving procedural safety. Her research emphasizes the integration of quantitative anatomical assessment into clinical workflows to enhance precision, reduce risk, and support safer invasive procedures. She has contributed to interdisciplinary studies that bridge anatomy, physiotherapy, clinical biomechanics, and medical engineering, strengthening the translation of scientific evidence into patient-centered practice. Her notable work includes the publication Predicting Median Nerve Depth from Anthropometric Features: A Tool for Safer Invasive Procedures, which examines how anthropometric predictors can guide clinicians in estimating nerve depth more accurately. Additionally, she co-authored the case report Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy, reflecting her engagement with clinically meaningful interventions and her involvement in research that intersects neuromuscular assessment and oncology-related neuropathy. With five indexed documents and collaborations with national and international researchers, her scholarship is gaining visibility, supported by a growing citation record that underscores the relevance of her work to emerging clinical methodologies. Through her commitment to methodological rigor and multidisciplinary inquiry, she aims to advance innovations that connect anatomical science, clinical decision-making, and technological development for improved patient outcomes and broader societal benefit. Sara Mogedano-Cruz’s academic influence and research productivity are reflected in her metrics: 18 citations, 5 documents, and an h-index of 1.

Profiles: Scopus | ORCID

Featured Publication

1. Mogedano-Cruz, S., González-de-la-Flor, Á., Rodríguez-Anadón, C., Bohn, L., Villafañe, J., & Romero-Morales, C. (2025). Predicting median nerve depth from anthropometric features: A tool for safer invasive procedures. PLoS ONE, 20(8), e0330383. (Cited by: 1).

Boya Guan | Medical Oncology | Best Researcher Award

Published on by NESIN Awards

Prof. Boya Guan | Medical Oncology | Best Researcher Award

Pharmacist-in-charge​ at Tianjin Hospital | China

Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.

Professional Profiles

Scopus Profile | ORCID Profile 

Education

Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.

Experience

With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.

Research Interest

Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.

Awards and Honors

Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.

Research Skills

Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.

Publication Top Notes

Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025

Conclusion

Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.

Praveen Neeli | Oncology | Best Researcher Award

Published on by NESIN Awards

Dr. Praveen Neeli | Oncology | Best Researcher Award

Research Scientist at Moffitt Cancer Center | United States

Dr. Praveen Kumar Neeli is a passionate and innovative researcher in the fields of cancer biology, immunotherapy, and vaccine development. His research focuses on advancing therapeutic strategies such as CAR-T cell therapies, DNA-based vaccines, and immune checkpoint targeting for cancer and autoimmune diseases. Currently positioned at UT MD Anderson Cancer Center, he contributes to high-impact projects that bridge laboratory research with clinical applications, thereby influencing the future of oncology treatments. He has published extensively in top-tier journals, authored review articles, and contributed book chapters that highlight his deep scientific expertise. His patents and collaborations with industry underscore his ability to translate research findings into practical medical solutions. With over 520 citations and a growing h-index, Dr. Neeli’s work demonstrates significant scientific impact. He also holds editorial and reviewer roles in several reputed journals, further establishing his leadership and commitment to the global research community.

Professional Profiles

Google Scholar | Scopus Profile | ORCID Profile 

Education

Dr. Neeli holds a Ph.D. in Applied Biology with a specialization in cancer biology from the CSIR-Indian Institute of Chemical Technology, where he explored the molecular mechanisms of breast cancer progression by studying metadherin splice variants. His doctoral research laid the foundation for his later interest in cancer therapeutics. Prior to his Ph.D., he completed a Master’s degree in Genetics and a Bachelor’s degree in Biotechnology, Biochemistry, and Chemistry from Osmania University, which gave him strong grounding in biological sciences and laboratory practices. To complement his scientific expertise, he also pursued a Postgraduate Diploma in Patent Law from NALSAR University, which provides him a valuable perspective on intellectual property rights and translational research. This combination of academic credentials showcases both depth and breadth, reflecting a balance between advanced molecular biology and broader interdisciplinary skills, enabling him to contribute effectively to cutting-edge research and innovation in cancer biology and immunotherapy.

Experience

Dr. Neeli has built extensive research experience through progressive roles in prestigious institutions across India and the United States. At UT MD Anderson Cancer Center, he works as a postdoctoral fellow developing CAR-T therapies to address both cancer and autoimmune diseases, a project with transformative clinical potential. Prior to this, at Baylor College of Medicine, he was involved in designing DNA-based vaccines targeting cancers and infectious diseases, further strengthening his expertise in immunology and molecular therapeutics. Earlier in his career, he contributed to projects at CSIR-Centre for Cellular and Molecular Biology and Osmania University, focusing on molecular biology techniques such as cloning, expression, and purification of proteins. These experiences have enabled him to develop mastery in molecular biology, cell biology, immunological assays, and translational cancer research. Additionally, his editorial and reviewer roles, mentorship of students, and participation in international conferences demonstrate both his leadership and active engagement in the research community.

Research Interest

Dr. Neeli’s primary research interests lie in the development of innovative cancer immunotherapies and vaccines that can translate into effective clinical solutions. His current focus is on CAR-T cell therapies, aiming to engineer immune cells to specifically target cancer and autoimmune disease mechanisms. He is equally passionate about DNA-based vaccines and antibody engineering, particularly for their potential to treat hematological malignancies, breast cancer, and solid tumors. His work bridges molecular biology, immunology, and translational medicine, reflecting a comprehensive approach to therapeutic innovation. Additionally, he is interested in understanding tumor microenvironments, immune modulation, and mechanisms of drug resistance in cancer progression. The intersection of basic science and clinical application excites him, as it allows for the creation of therapies that directly benefit patients. He is also keen on exploring collaborative, multidisciplinary projects that integrate molecular biology with bioinformatics and clinical oncology to address unmet medical needs in cancer treatment.

Awards and Honors

Throughout his career, Dr. Neeli has been recognized with numerous awards and fellowships that highlight his academic and research excellence. He was awarded the ICMR Doctoral Research Fellowship, a highly competitive fellowship in India, which supported his Ph.D. work on breast cancer biology. His outstanding performance in national-level examinations such as GATE, CSIR-NET, and AP-SET further reflect his strong academic foundation and scientific aptitude. He has also actively participated in prestigious conferences including the American Association of Cancer Research (AACR) Annual Meeting, International Chemical Biology Society (ICBS), and other global research forums, showcasing his work to international audiences. His recognition extends beyond research fellowships to patents and technology development, with compounds licensed to pharmaceutical industries, which demonstrates the translational value of his contributions. These awards and achievements reflect not only his scientific excellence but also his commitment to bridging fundamental research with clinical and industrial applications.

Research Skills

Dr. Neeli possesses a diverse and advanced set of research skills spanning molecular biology, cell biology, immunology, and translational oncology. He is highly skilled in techniques such as cloning, gene expression, protein purification, site-directed mutagenesis, and chromatin immunoprecipitation. His expertise extends to advanced immunological methods, including ELISA, ELISPOT, flow cytometry, immune cell sorting, co-culture assays, and CAR-T cell engineering. He has significant experience in mammalian cell culture, confocal microscopy, and live imaging, as well as handling small animal models for preclinical studies. His work also involves bioinformatics tools for scientific analysis and visualization, combined with strong skills in scientific writing and communication. Additionally, his patents and translational projects highlight his capacity to move from bench research to industry-level applications. These skills collectively position him as a versatile and impactful researcher, capable of addressing complex biomedical challenges and contributing meaningfully to the advancement of cancer immunotherapy and vaccine development.

Publication Top Notes

Title: Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction
Authors: S. Karnewar, P.K. Neeli, D. Panuganti, S. Kotagiri, S. Mallappa, N. Jain, et al.
Year: 2018
Citation: 147

Title: The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
Authors: B. Lu, J.M. Lim, B. Yu, S. Song, P. Neeli, N. Sobhani, P.K., S.R. Bonam, et al.
Year: 2024
Citation: 95

Title: Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Authors: N. Sobhani, B. Scaggiante, R. Morris, D. Chai, M. Catalano, D.R. Tardiel-Cyril, P. Neeli, et al.
Year: 2022
Citation: 77

Title: AR-V7 in metastatic prostate cancer: a strategy beyond redemption
Authors: N. Sobhani, P.K. Neeli, A. D’Angelo, M. Pittacolo, M. Sirico, I.C. Galli, et al.
Year: 2021
Citation: 64

Title: AMPK inhibits MTDH expression via GSK 3β and SIRT 1 activation: potential role in triple negative breast cancer cell proliferation
Authors: P.N. Gollavilli, A.K. Kanugula, R. Koyyada, S. Karnewar, P.K. Neeli, et al.
Year: 2015
Citation: 59

Title: A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis
Authors: P.K. Neeli, P.N. Gollavilli, S. Mallappa, S.G. Hari, S. Kotamraju
Year: 2020
Citation: 41

Title: Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function
Authors: S. Karnewar, S. Pulipaka, S. Katta, D. Panuganti, P.K. Neeli, R. Thennati, et al.
Year: 2022
Citation: 37

Title: Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization
Authors: S. Mallappa, P.K. Neeli, S. Karnewar, S. Kotamraju
Year: 2019
Citation: 35

Title: Expanding anti-CD38 immunotherapy for lymphoid malignancies
Authors: M.Z.Y.L., X. Wang, X. Yu, W. Li, P. Neeli, M. Liu, L. Li
Year: 2022
Citation: 31

Title: p53 antibodies as a diagnostic marker for cancer: A meta-analysis
Authors: N. Sobhani, G. Roviello, A. D’Angelo, R. Roudi, P.K. Neeli, D. Generali
Year: 2021
Citation: 22

Title: DOT1L regulates MTDH mediated angiogenesis in triple-negative breast cancer: Intermediacy of NF-κB-HIF1α axis
Authors: P.K. Neeli, S. Sahoo, S. Karnewar, G. Singuru, S. Pulipaka, S. Annamaneni, et al.
Year: 2022
Citation: 16

Title: AI-powered discovery of a novel p53-Y220C reactivator
Authors: Y. Li, S. Zhou, D. Chai, X. Wang, P. Neeli, X. Yu, A. Davtyan, K. Young
Year: 2023
Citation: 11

Conclusion

Dr. Praveen Kumar Neeli is a highly deserving candidate for the Best Researcher Award. His cutting-edge research in CAR-T therapies, DNA vaccines, and cancer biology demonstrates both scientific depth and translational impact. With multiple high-impact publications, patents, international collaborations, and community contributions, he stands out as a researcher who not only advances knowledge but also contributes meaningfully to clinical applications and society. His growing leadership roles, strong academic foundation, and ongoing projects position him as a promising future leader in oncology and immunotherapy research.

Tanmay Kulkarni | Cancer Biology | Best Researcher Award

Published on by NESIN Awards

Dr. Tanmay Kulkarni | Cancer Biology | Best Researcher Award

Assistant Professor at Mayo Clinic Florida, United States

Dr. Tanmay Kulkarni is a highly accomplished research professional with over 12 years of publication experience and 7+ years in academic and clinical research settings, currently serving as Assistant Professor and Research Associate at Mayo Clinic. With a multidisciplinary background in electrical engineering and biomedical sciences, he has authored numerous high-impact publications and led innovative projects involving nanomechanical analysis, tumor microenvironments, and biosensing systems. His contributions include serving as a guest editor for special issues, submitting NIH and DoD grants, and mentoring young researchers. Dr. Kulkarni’s technical expertise spans advanced microscopy, data analysis, and scientific writing. His leadership in research, coupled with editorial and peer-review roles across multiple journals, showcases his influence in the scientific community. Recognized with awards and invited presentations, his dedication to translational science and academic excellence positions him as a strong candidate for the Best Researcher Award. He exemplifies innovation, collaboration, and impactful scientific contribution.

Professional Profile 

Education🎓

Dr. Tanmay Kulkarni holds a robust academic background in electrical and electronics engineering, which laid the foundation for his multidisciplinary research career. He earned his Doctor of Philosophy (Ph.D.) in Electrical Engineering from the University of Maryland, Baltimore County (UMBC) in 2017, where his doctoral work focused on developing a self-powered biosensing system capable of simultaneously sensing glucose and powering microelectronic devices—a novel concept with potential clinical applications. Prior to that, he completed his Master of Science (M.S.) in Electrical Engineering from UMBC in 2014, where he was involved in collaborative biomedical imaging research analyzing adipose tissue distribution in hyperglycemic baboons. He began his academic journey with a Bachelor of Engineering in Electronics and Telecommunication from Mumbai University in 2012. Throughout his educational path, Dr. Kulkarni has consistently demonstrated strong analytical, experimental, and collaborative skills, integrating engineering principles with biomedical applications, which continue to drive his success in translational research.

Professional Experience📝

Dr. Tanmay Kulkarni brings extensive professional experience spanning over seven years in top-tier research environments, primarily at the Mayo Clinic in Jacksonville, Florida. Currently serving as an Assistant Professor and Research Associate, he leads projects focused on tumor microenvironments, cell-matrix interactions, and nanomechanical analysis using advanced microscopy techniques. He previously held roles as Senior Research Fellow and Research Fellow, where he contributed to groundbreaking studies involving atomic force microscopy, Raman spectroscopy, and biosensor development. Dr. Kulkarni has authored and co-authored numerous high-impact publications, presented at prestigious symposia, and submitted competitive NIH and DoD grants as a principal and co-investigator. His leadership extends to editorial roles, including guest editor for special journal issues and reviewer for several high-impact journals. He has also mentored students through programs like SPARK and SURF, reflecting his commitment to scientific mentorship. His career reflects a balance of innovation, collaboration, and academic excellence in translational biomedical research.

Research Interest🔎

Dr. Tanmay Kulkarni’s research interests lie at the intersection of engineering, biology, and medicine, with a strong focus on translational applications. His primary areas of interest include tumor microenvironment (TME) dynamics, nanomechanical characterization of biological tissues, biosensor development, and cell-extracellular matrix interactions. He is particularly passionate about leveraging advanced microscopy techniques—such as atomic force microscopy, confocal imaging, and Raman spectroscopy—to explore disease mechanisms at the molecular and cellular level. Dr. Kulkarni is also deeply involved in developing self-powered biosensing systems that integrate biofuel cells for real-time health monitoring and energy-efficient diagnostics. His recent work focuses on understanding the immunological landscape in cancer biopsies, designing biomaterials for drug delivery, and identifying extracellular vesicle signatures for neurodegenerative and metabolic diseases. By combining quantitative engineering tools with biological insight, Dr. Kulkarni aims to contribute to early disease detection, targeted therapy, and personalized medicine, making meaningful strides in biomedical engineering and clinical research.

Award and Honor🏆

Dr. Tanmay Kulkarni has received several prestigious awards and honors that reflect his outstanding contributions to biomedical research and scientific innovation. He was honored with the Outstanding Abstract Certificate at the 9th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk in 2022, recognizing the significance and impact of his research on immune-tumor interactions. Additionally, he earned the Best Poster Presentation Award at the same symposium, further highlighting the excellence of his scientific communication. Dr. Kulkarni’s inclusion in Marquis Who’s Who in November 2024 acknowledges his professional achievements and influence in the scientific community. His appointment as Guest Editor for special issues in leading journals and his roles on editorial and reviewer boards—including Frontiers in Bioengineering and Biotechnology, European Journal of Biophysics, and Biosensors Journal—underscore his leadership and service to the field. These accolades collectively reflect his innovation, academic rigor, and dedication to advancing translational biomedical science.

Research Skill🔬

Dr. Tanmay Kulkarni possesses a diverse and advanced set of research skills that support his multidisciplinary investigations in biomedical science and engineering. He is highly proficient in designing and conducting complex experiments, particularly those involving atomic force microscopy, confocal imaging, Raman spectroscopy, and biomaterials characterization. Dr. Kulkarni is skilled in statistical data analysis, figure preparation, and manuscript development, having authored numerous high-impact publications. His technical expertise extends to software tools such as GraphPad Prism, Origin, ImageJ, MATLAB, Biorender, and Endnote, which he uses for data visualization and scientific reporting. He is experienced in NIH grant writing and has successfully submitted multiple research proposals as a principal and co-investigator. Furthermore, he is adept at scientific editing, proofreading, and adhering to journal-specific guidelines, often serving as a reviewer and editorial board member for reputed journals. Dr. Kulkarni’s strengths also include interdisciplinary collaboration and mentoring, enabling impactful research across engineering, biology, and clinical domains.

Conclusion💡

Dr. Tanmay Kulkarni is an excellent candidate for the Best Researcher Award. His outstanding publication record, multidisciplinary expertise, editorial leadership, and sustained scientific productivity make him highly deserving of this recognition. With continued focus on broader impact and recognition, his profile will only grow stronger. His application would stand out among nominees due to its depth, breadth, and alignment with innovation and academic excellence.

Publications Top Noted✍️

  • Slaughter, G. & Kulkarni, T. (2015)
    Title: Enzymatic glucose biofuel cell and its application
    Journal: Journal of Biochips & Tissue Chips, 5(1), 1
    Citations: 104

  • Slaughter, G. & Kulkarni, T. (2016)
    Title: A self-powered glucose biosensing system
    Journal: Biosensors and Bioelectronics, 78, 45-50
    Citations: 102

  • Kulkarni, T. & Slaughter, G. (2016)
    Title: Application of semipermeable membranes in glucose biosensing
    Journal: Membranes, 6(4), 55
    Citations: 84

  • Slaughter, G. & Kulkarni, T. (2017)
    Title: Highly selective and sensitive self-powered glucose sensor based on capacitor circuit
    Journal: Scientific Reports, 7(1), 1471
    Citations: 76

  • Kulkarni, T. & Slaughter, G. (2017)
    Title: Characteristics of two self-powered glucose biosensors
    Journal: IEEE Sensors Journal, 17(12), 3607–3612
    Citations: 34

  • Slaughter, G. & Kulkarni, T. (2016)
    Title: Fabrication of palladium nanowire array electrode for biofuel cell application
    Journal: Microelectronic Engineering, 149, 92–96
    Citations: 33

  • Kulkarni, T., Tam, A., Mukhopadhyay, D., & Bhattacharya, S. (2019)
    Title: AFM study: Cell cycle and probe geometry influences nanomechanical characterization of Panc1 cells
    Journal: Biochimica et Biophysica Acta (BBA) – General Subjects, 1863(5), 802–812
    Citations: 29

  • Arthur, P., Kandoi, S., Sun, L., Kalvala, A., Kutlehria, S., Bhattacharya, S., … (Kulkarni, T.) (2023)
    Title: Biophysical, molecular and proteomic profiling of human retinal organoid-derived exosomes
    Journal: Pharmaceutical Research, 40(4), 801–816
    Citations: 28

  • Slaughter, G. & Kulkarni, T. (2019)
    Title: Detection of human plasma glucose using a self-powered glucose biosensor
    Journal: Energies, 12(5), 825
    Citations: 23

  • Kulkarni, T. & Slaughter, G. (2016)
    Title: Self-powered glucose biosensor operating under physiological conditions
    Conference: 2016 IEEE SENSORS, 1–3
    Citations: 22

  • Kulkarni, T., Angom, R.S., Das, P., Bhattacharya, S., & Mukhopadhyay, D. (2019)
    Title: Nanomechanical insights: Amyloid beta oligomer-induced senescent brain endothelial cells
    Journal: BBA – Biomembranes, 1861(12), 183061
    Citations: 21

William Skelton | Medical Oncology | Best Researcher Award

Published on by NESIN Awards

Dr. William Skelton | Medical Oncology | Best Researcher Award

Assistant Professor of Medicine at University of Virginia Comprehensive Cancer Center, United States

Dr. William Paul Skelton IV is an Assistant Professor of Medicine at the University of Virginia School of Medicine, specializing in Hematology and Oncology. With extensive training from prestigious institutions like Moffitt Cancer Center and the University of Florida, Dr. Skelton is a dedicated clinician and researcher in Genitourinary Oncology. His career is marked by numerous awards, including recognition for excellence in patient care and teaching. Dr. Skelton is committed to advancing cancer treatment through research and has a notable record of impactful publications and presentations in the field. His professional contributions extend to mentoring and serving on various academic committees.

Publication Profile

Education

Dr. William Paul Skelton IV completed his Hematology/Oncology Fellowship at Moffitt Cancer Center, University of South Florida, followed by a Chief Medical Residency at the University of Florida. He earned his Internal Medicine Residency from the same institution and graduated with honors in research from the University of Florida College of Medicine. Dr. Skelton holds a Magna Cum Laude degree in Chemistry from Duke University and a high school diploma with exceptional achievements from King International Baccalaureate High School.

Experience

Dr. Skelton’s professional journey includes his current role as an Assistant Professor of Medicine at the University of Virginia School of Medicine. Previously, he served as a Hematology/Oncology Fellow at Moffitt Cancer Center and as a Chief Medical Resident during his Internal Medicine Residency at the University of Florida. His clinical expertise encompasses Genitourinary Oncology, and he has contributed significantly to medical education through precepting and mentoring medical students, residents, and fellows.

Awards and Honors

Dr. Skelton has received several prestigious awards, including the Moffitt Cancer Center SPOTTED in FellowSHIP patient care Recognition Award in both 2020 and 2021. He was honored with the Florida ACP Chief Resident Award and the UF Senior Resident Medical Student Teaching Award. Additional accolades include the Craig S. Kitchens Outstanding Senior Medicine Resident Award and selection into the Alpha Omega Alpha Honor Society. His academic honors also include Phi Beta Kappa and the Merck Index Award.

Research Focus

Dr. Skelton’s research primarily focuses on Genitourinary Oncology, particularly the therapeutic advancements and molecular mechanisms underlying renal and bladder cancers. His work includes investigating predictive tools for advanced renal cancer and exploring the impact of systemic therapies on cancer progression. Dr. Skelton’s research is aimed at improving patient outcomes through innovative treatment strategies and clinical trials.

Publications Top Notes

  • Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    • Authors: Skelton, W.P., Masur, J., Thomas, J., Jain, R.K., Sonpavde, G.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 💊💉🩺
  • Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus
    • Authors: Ali, S., Fortune, K., Masur, J., Dreicer, R., Skelton, W.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 🩸👨‍⚕️🧬
  • Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer
    • Authors: Altshuler, E., Franke, A.J., Skelton, W.P., Dai, Y., George, T.J.
    • Journal: Clinical Colorectal Cancer
    • Year: 2023
    • Citations: 2 🧬🔬
  • Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
    • Authors: Zhang, Y., Kumar, P., Adashek, J.J., Manley, B.J., Spiess, P.E.
    • Journal: Cells
    • Year: 2022
    • Citations: 6 🧫🔬💊
  • FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    • Authors: Adib, E., El-Zarif, T., Jain, R.K., Choueiri, T.K., Sonpavde, G.P.
    • Journal: BJUI Compass
    • Year: 2022
    • Citations: 6 🧬💉🧪
  • Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
    • Authors: Skelton, W.P., Dahmen, A., Chatwal, M., Chahoud, J., Spiess, P.E.
    • Book Chapter: Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
    • Year: 2022
    • Citations: 0 📖🦠💉
  • Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration
    • Authors: Ravi, P., Pond, G.R., Diamantopoulos, L.N., Grivas, P., Sonpavde, G.P.
    • Journal: BJU International
    • Year: 2021
    • Citations: 13 🧬🌍
  • Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
    • Authors: Starr, J.S., Skelton, W.P., Rahmanian, K.P., George, T.J., Moseley, R.E.
    • Journal: Journal of Palliative Care
    • Year: 2021
    • Citations: 0 📊🩺📋
  • A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
    • Authors: Franke, A.J., Skelton, W.P., George, T.J., Iqbal, A.
    • Journal: Clinical Colorectal Cancer
    • Year: 2021
    • Citations: 4 🧪📊
  • Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    • Authors: Adashek, J.J., Zhang, Y., Skelton, W.P., Manley, B., Spiess, P.E.
    • Journal: Frontiers in Oncology
    • Year: 2021
    • Citations: 5 🧬🩺💉

Fan Yang | Radiation Oncology | Best Scholar Award

Published on by NESIN Awards

🌟Dr. Fan Yang, Radiation Oncology, Best Researcher Award🏆

Doctorate at Memorial Sloan Kettering Cancer Center, United States

Dr. Fan Yang is a highly accomplished radiation oncologist with expertise in proton therapy and extensive experience in research, education, and leadership roles. His educational background includes a Doctor of Medicine from the University of British Columbia, residency at the University of Alberta, and a Proton Therapy Clinical and Research Fellowship at Memorial Sloan Kettering Cancer Center. He holds numerous licenses and certifications, including from the American Board of Radiology and the Royal College of Physicians and Surgeons of Canada. Dr. Yang has received multiple awards for his research and academic achievements.

Author Metrics:

Google Scholar Profile

Dr. Yang has authored several book chapters, published original manuscripts, and presented his work at numerous national and international conferences. He serves as an editor and reviewer for prominent medical journals, contributing to the advancement of radiation oncology and related fields.

  • 178 total citations
  • An h-index of 7, indicating that they have published 7 papers that have each been cited at least 7 times
  • An i10-index of 7, which means that they have published 7 papers that have been cited at least 10 times each

Education:

  • Doctor of Medicine, University of British Columbia
  • Proton Therapy Clinical and Research Fellowship, Memorial Sloan Kettering Cancer Center

Research Focus:

Dr. Yang’s research interests span various aspects of radiation oncology, including treatment outcomes, toxicity prediction, and novel therapeutic approaches. His work encompasses a wide range of cancers, with a particular focus on head and neck, prostate, glioblastoma, and rectal cancers.

Professional Journey:

Dr. Yang’s professional journey includes leadership roles such as Chief Resident and various committee memberships, demonstrating his commitment to education, resident wellness, and program development. He has also been involved in instructing and mentoring radiation therapy trainees.

Honors & Awards:

Dr. Yang has received several prestigious awards, including Best Resident Research Award, Academic Excellence Award, and RSNA Resident Research Award, recognizing his outstanding contributions to the field of radiation oncology.

Publications Noted & Contributions:

Dr. Yang has authored numerous peer-reviewed publications, covering diverse topics within radiation oncology, including treatment strategies, quality of life outcomes, predictive modeling, and interdisciplinary collaboration. His research contributions have been featured in high-impact journals and media outlets.

“Osteoradionecrosis Rates Following Head and Neck Radiotherapy: Beyond the Numbers”

  • Journal: Practical Radiation Oncology
  • Year: 2024

“Incidence of Flap Failure Following Sinonasal Surgery, Flap Reconstruction and Postoperative Proton Radiation Therapy”

  • Journal: International Journal of Radiation Oncology, Biology, Physics
  • Volume: 118
  • Issue: 5
  • Page: e53
  • Year: 2024

“Radiation Oncology for the Rhinologist”

  • Journal: Current Opinion in Otolaryngology & Head and Neck Surgery
  • Volume: 32
  • Issue: 1
  • Pages: 5-13
  • Year: 2024

“Design and Implementation of a Multidisciplinary High-Fidelity Simulation Course for the Management of Malignant Spinal Cord Compression”

  • Journal: Journal of Cancer Education
  • Volume: 38
  • Issue: 6
  • Pages: 1939-1947
  • Year: 2023

“Successful Implementation of a Radiation Therapist-Led Interdisciplinary Course for Learning Malignant Spinal Cord Compression Management”

  • Journal: Radiotherapy and Oncology
  • Volume: 186
  • Page: S11
  • Year: 2023

Research Timeline:

Dr. Yang’s research timeline demonstrates a consistent and prolific output, with a trajectory of impactful contributions throughout his career. From his early involvement in summer research programs to his fellowship and beyond, he has maintained a dedication to advancing the field through rigorous scientific inquiry.

Collaborations and Projects:

Dr. Yang has collaborated with multidisciplinary teams and contributed to various collaborative projects, enhancing the understanding and treatment of cancer. His involvement in simulation-based learning modules and quality improvement initiatives underscores his commitment to innovation and excellence in patient care.